The prevalence of anti-HBc was higher for those individuals with coagulopathy (GIII) who had already undergone blood or plasma transfusion (p = 0.018) and for blood transfusions performed before 1994 (p = 0.076), since testing for anti-HCV became a mandatory component of serological screening conducted at Brazilian blood banks after November 1993. This evidence concerns the gene KRT88P and blood coagulation disease.